Human Immunoglobulins for intravenous use and hepatitis C viral transmission

Slade, Herbert B.

doi:10.1128/cdli.1.6.613-619.1994

Cited by 22 publications

(6 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is significant variation in pathogen-specific opsonic activity of commercially available immunoglobulin preparations [94]. There is also concern about the potential of human sera to transmit infectious agents [95].…”

Section: Advances In Mab Technologiesmentioning

confidence: 99%

Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases

Casadevall

Scharff²

1995

Clinical Infectious Diseases

304

205

View full text Add to dashboard Cite

In the preantibiotic era, passive antibody administration (serum therapy) was useful for the treatment of many infectious diseases. The introduction of antimicrobial chemotherapy in the 1940s led to the rapid abandonment of many forms of passive antibody therapy. Chemotherapy was more effective and less toxic than antibody therapy. In this last decade of the 20th century the efficacy of antimicrobial chemotherapy is diminishing because of the rapidly escalating number of immunocompromised individuals, the emergence of new pathogens, the reemergence of old pathogens, and widespread development of resistance to antimicrobial drugs. This diminishment in the effectiveness of chemotherapy has been paralleled by advances in monoclonal antibody technology that have made feasible the generation of human antibodies. This combination of factors makes passive antibody therapy an option worthy of serious consideration. We propose that for every pathogen there exists an antibody that will modify the infection to the benefit of the host. Such antibodies are potential antimicrobial agents. Antibody-based therapies have significant advantages and disadvantages relative to standard chemotherapy. The reintroduction of antibody-based therapy would require major changes in the practices of infectious disease specialists.

show abstract

Section: Advances In Mab Technologiesmentioning

confidence: 99%

Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases

Casadevall

Scharff²

1995

Clinical Infectious Diseases

304

205

View full text Add to dashboard Cite

show abstract

“…In prevalence studies completed in the wake of contaminated blood products, there was not a significant number of asymptomatic patients carrying viral hepatitis viruses . Of note, there was a discrepancy between countries on the testing and use of pooled serum prior to molecular testing for HCV viral RNA . In excluding all pools containing HCV antibody positive donors, physicians in the United States may have inadvertently increased infection incidence or severity compared with pools containing potentially neutralising antibody, although this remains unproven.…”

Section: Hepacivirusesmentioning

confidence: 88%

Viral infection in primary antibody deficiency syndromes

Jones

Buckland

Breuer

et al. 2019

Reviews in Medical Virology

View full text Add to dashboard Cite

Patients with primary antibody deficiency syndromes such as X-linked agammaglobulinemia (XLA) and common variable immunodeficiency (CVID) are at increased risk of severe and invasive infection. Viral infection in these populations has been of increasing interest as evidence mounts that viruses contribute significant morbidity and mortality: this is mediated both directly and via aberrant immune responses.We explain the importance of the humoral immune system in defence against viral pathogens before highlighting several significant viral syndromes in patients with antibody deficiency.We explore historical cases of hepatitis C via contaminated immunoglobulin products, the predisposition to invasive enteroviral infections, prolonged excretion of vaccinederived poliovirus, the morbidity of chronic norovirus infection, and recent literature revealing the importance of respiratory viral infections. We discuss evidence that herpesviruses may play a role in driving the inflammatory disease seen in a subset of patients. We explore the phenomenon of within-host evolution during chronic viral infection and the potential emergence of new pathogenic strains. We highlight novel and emerging viruses identified via deep sequencing techniques. We describe the treatment strategies that have been attempted in all these scenarios and the urgent outstanding questions for research.

show abstract

“…For example, in a comparison of the activity of human MAbs with that of human immune globulin, 0.7 mg of a mixture of two MAbs had the same neutralizing activity as 100 mg–170 mg of tetanus immune globulin ( 90 ). Other problems associated with polyclonal preparations generated from immune donors are lot-to-lot variations in the amount of specific antibody ( 91 ), limited supply ( 92 ), and the possibility of transmission of infectious agents ( 93 ).…”

Section: Polyclonal Versus Mab Productsmentioning

confidence: 99%

Passive Antibody Administration (Immediate Immunity) as a Specific Defense Against Biological Weapons

Casadevall¹

2002

Emerg. Infect. Dis.

154

View full text Add to dashboard Cite

The potential threat of biological warfare with a specific agent is proportional to the susceptibility of the population to that agent. Preventing disease after exposure to a biological agent is partially a function of the immunity of the exposed individual. The only available countermeasure that can provide immediate immunity against a biological agent is passive antibody. Unlike vaccines, which require time to induce protective immunity and depend on the host’s ability to mount an immune response, passive antibody can theoretically confer protection regardless of the immune status of the host. Passive antibody therapy has substantial advantages over antimicrobial agents and other measures for postexposure prophylaxis, including low toxicity and high specific activity. Specific antibodies are active against the major agents of bioterrorism, including anthrax, smallpox, botulinum toxin, tularemia, and plague. This article proposes a biological defense initiative based on developing, producing, and stockpiling specific antibody reagents that can be used to protect the population against biological warfare threats.

show abstract

Human Immunoglobulins for intravenous use and hepatitis C viral transmission

Cited by 22 publications

References 52 publications

Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases

Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases

Viral infection in primary antibody deficiency syndromes

Passive Antibody Administration (Immediate Immunity) as a Specific Defense Against Biological Weapons

Contact Info

Product

Resources

About